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Previous reports have drawn attention to persistently decreased platelet counts among liver donors. We hypothesized an etiologic
association between altered platelet counts and postdonation splenomegaly and sought to explore this relationship. This study ana-
lyzed de-identified computed tomography/magnetic resonance scans of 388 donors from 9 Adult-to-Adult Living Donor Liver Trans-
plantation Cohort Study centers read at a central computational image analysis laboratory. Resulting liver and spleen volumes were
correlated with time-matched clinical laboratory values. Predonation liver volumes varied 2-fold in healthy subjects, even when they
were normalized by the body surface area (BSA; range5 522-1887 cc/m2, n5 346). At month 3 (M3), postdonation liver volumes
were, on average, 79% of predonation volumes [interquartile range (IQR)5 73%-86%, n5 165] and approached 88% at year 1 (Y1;
IQR5 80%-93%, n575). The mean spleen volume before donation was 245 cc (n5346). Spleen volumes greater than 100% of
the predonation volume occurred in 92% of donors at M3 (n5 165) and in 88% at Y1 after donation (n5 75).We sought to develop a
standard spleen volume (SSV) model to predict normal spleen volumes in donors before donation and found that decreased platelet
counts, a younger age, a higher predonation liver volume, higher hemoglobin levels, and a higher BSA predicted a larger spleen vol-
ume (n5344, R250.52). When this was applied to postdonation values, some large volumes were underpredicted by the SSV
model. Models developed on the basis of the reduced sample of postdonation volumes yielded smaller underpredictions. These find-
ings confirm previous observations of thrombocytopenia being associated with splenomegaly after donation. The results of the SSV
model suggest that the biology of this phenomenon is complex. This merits further long-termmechanistic studies of liver donors with
an investigation of the role of other factors such as thrombopoietin and exposure to viral infections to better understand the evolution
of the spleen volume after liver donation.Liver Transpl 21:151-161, 2015.VC 2014AASLD.
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Although living donor liver transplantation (LDLT) has a
high success rate1,2 and increases access to transplanta-
tion,2 concerns about donor safety and the technical com-
plexity of the recipient operation have greatly limited
expansion of the procedure inWestern countries. Although
LDLT is the principal donor source for liver transplantation
inAsian countries,3,4 LDLThas accounted for less than5%
of procedures performed annually in the United States in
the past 5 years. Unfortunately, the limited use of LDLT
persists despite the demonstration of safety in the donors
and efficacy in the recipients. There is a compelling survival
benefit for the recipient in choosing LDLT5 even among
Additional Supporting Information may be found in the online version of this article.
Abbreviations: A2ALL, Adult-to-Adult Living Donor Liver Transplantation Cohort Study; ALT, alanine aminotransferase; AP, alka-
line phosphatase; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; CT, computed tomography;
INR, international normalized ratio; IQR, interquartile range; LDLT, living donor liver transplantation; M3, month 3; MR, magnetic
resonance; SD, standard deviation; SSV, standard spleen volume; Y1, year 1
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patients with Model for End-Stage Liver Disease scores as
low as 10,6 and the morbidity of donation in a large multi-
center trial of LDLT7 was acceptable, as previously
observed in single-center studies.
Despite the apparent preexisting good health and early
clinical recovery of most donors, abnormal laboratory
tests were noted in some subjects at least at year 1 (Y1)
after donation. We first reported a persistent decline in
platelet counts through Y1 after donation in a subset of
liver donors from a single center in 2004.8 This finding
was subsequently observed in the much larger Adult-to-
Adult Living Donor Liver Transplantation Cohort Study
(A2ALL).9 In the 487 subjects in that cohort, platelet
counts were significantly decreased at Y1 for the popula-
tion as a whole and were below the lower limit of normal
in 7% of 327 subjects with normal laboratory values
before donation who were at Y1 or longer after donation.
In a substudy of quantitative liver function of A2ALL
donors, we noted that splenomegaly in some subjects
corresponded to decreased platelet counts.10
In the current study, we sought to determine whether
abnormal laboratory tests after donation were associated
TABLE 1. Characteristics of 388 Living Liver Donors
Characteristic n
Mean (SD)
or % Range
Age (years) 388 37.8 (10.4) 18.2-62.7
Sex
Male 189 48.7
Female 199 51.3
Ethnicity
Hispanic 53 13.7
Non-Hispanic 335 86.3
Race
White 359 92.5
African American 11 2.8
Asian 6 1.6
Other 12 3.1
Height (cm) 388 171.8 (10.2) 134.6-195.6
Weight (kg) 388 77.9 (14.8) 43.1-135.0
BMI (kg/m2) 388 26.3 (3.9) 16.4-42.4
Left lobe donor 25 6.4
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with splenomegaly or volumetric alterations in the liver
by examining the relationship between liver and spleen
volumes and the evolution of laboratory tests up to Y1
after donation. Because spleen size is associated with
platelet counts and may be an indicator of portal hyper-
tension, we sought to characterize normal spleen volume
before donation and changes after donor partial hepatec-
tomy. In addition, we sought to identify predictors of
abnormal laboratory tests and to identify a subset of sub-
jects at risk for marked splenomegaly after donation.
PATIENTS AND METHODS
A2ALL was an observational study at 9 US centers that
was conducted to evaluate the efficacy of LDLT in adult
recipients and to characterize the impact of donation on
healthy subjects. Computed tomography (CT)/magnetic
resonance (MR) scans were collected for 388 subjects
who underwent donor hepatectomy between July 1998
and May 2010. Demographic and clinical variables were
collected both prospectively and retrospectively with
follow-up to 11 years after donation. The study was
approved by the institutional review boards and privacy
boards of the University of Michigan Data Coordinating
Center and each of the transplant centers.
Imaging and Analysis
CT/MR scans before donation and at month 3 (M3)
and Y1 after donation were collected when they were
available from the study sites, de-identified, and
transmitted with AG Mednet’s system (AG Mednet,
TABLE 2. Donor Laboratory Values and Liver and Spleen Volumes by Time Point: Before Donation and After Donation
at M3 and Y1
Pre-Donation M3 Y1
Laboratory values at each time point
Albumin (g/dL) 4.4 (0.4) 4.1 (0.4)* 4.2 (0.4)*
3.5-5.5 2.8-5.2 2.9-5.2
387 265 192
Bilirubin (mg/dL) 0.7 (0.3) 0.7 (0.4) 0.8 (0.3)*
0.1-2.8 0.1-3.6 0.2-2.6
388 272 197
ALT (IU/L) 24.4 (12.5) 29.5 (16.5)* 25.2 (13.5)
4.0-110.0 1.5-108.0 6.0-92.0
388 272 195
AST (IU/L) 23.3 (6.6) 29.9 (13.9)* 26.1 (11.0)*
11.0-53.0 13.0-130.0 11.0-109.0
387 272 197
AP (IU/L) 68.4 (24.8) 93.8 (42.9)* 74.1 (26.3)*
15.0-197.0 30.0-385.0 16.0-186.0
388 271 196
INR 1.00 (0.08) 1.05 (0.09)* 1.02 (0.09)*
0.78-1.50 0.89-1.70 0.70-1.50
382 254 186
Platelet count (3103/mm3) 264.3 (63.0) 221.6 (67.6)* 214.4 (63.7)*
126.0-543.0 94.0-660.0 3.6-708.0
387 270 192
White blood count (3103/mm3) 6.6 (1.8) 6.6 (1.7) 6.6 (1.7)
3.1-20.7 0.9-14.0 3.4-16.4
387 269 194
Hemoglobin (g/dL) 14.6 (1.4) 13.7 (1.8)* 14.4 (1.5)*
9.1-18.4 5.4 17.3 9.4-18.0
387 268 192
Volumes at each time point
Liver volume (cc) 1601.0 (327.3) 1241.2 (257.1)* 1440.5 (274.0)*
863.8-3250.8 790.0-2024.1 936.3-2122.0
346 182 90
Spleen volume (cc) 245.6 (107.3) 314.3 (136.4)* 323.6 (181.4)*
67.1-774.6 77.6-842.2 82.5-1171.7
346 182 90
Liver/spleen Ratio 7.4 (2.8) 4.6 (1.8)* 5.5 (2.6)*
2.5-22.8 1.7-11.2 1.2-15.9
346 182 90
NOTE: For all values, the first row gives the mean (SD), the second row gives the range, and the third row gives the n
value.
*Significantly different from the predonation value (P<0.05) according to a paired t test.
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Inc., Boston, MA) to the central Computational Image
Analysis Laboratory of Columbia University Medical
Center.11,12
Images were coded to permit merging with clinical
information. Liver and spleen volumes were calculated
with a proprietary, organ-generic algorithm developed
by the Computational Image Analysis Laboratory.
Scan-based volumes were correlated with clinical and
laboratory features at corresponding times.
Statistical Methods
We used means, standard deviations (SDs), ranges,
box plots, and percentages to describe donor charac-
teristics by time point. Correlation coefficients and
scatter plots were used to assess relationships
between corresponding variables at different time
points as well as different variables at the same time
point. Spaghetti plots were used to assess within-
person trends in variables over time.
Linear regression was used to model the predona-
tion spleen volume as a function of laboratory and
patient characteristics. Variables tested in the model
included the body surface area (BSA), height, weight,
body mass index (BMI), age, sex, predonation liver
volume, platelet count, white blood cell count, and
hemoglobin. The model fit was assessed with R2,
leverage and influence diagnostics, and residual plots.
Variable selection was performed with the method of
best subsets. Logistic regression was used to test pre-
dictors of predonation spleen volumes greater than
400 cc. All analyses were performed with SAS 9.2
(SAS Institute, Inc., Cary, NC).
RESULTS
Donor characteristics are summarized in Table 1. The
sex distribution was nearly equal, and the majority of
donors were white (92.5%) and non-Hispanic (86.3%).
Heights ranged from 134.6 to 195.6 cm, and weights
ranged from 43.1 to 135.0 kg. Although the mean BMI
was 26.3 kg/m2, the range was substantial and
included subjects in the overweight and even obese cat-
egories [interquartile range (IQR)523.3-28.8 kg/m2,
range516.4-42.4 kg/m2]. Only 25 subjects (6.4%) were
left lobe donors.
Table 2 summarizes the laboratory and organ vol-
ume data before donation and at M3 and Y1. Several
laboratory tests of liver function [albumin, bilirubin,
aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alkaline phosphatase (AP), and
international normalized ratio (INR)] were significantly
different from predonation values at M3 and/or Y1,
although the changes were small and generally
remained in the normal range. Similarly, alterations
in the hematologic profiles were seen for hemoglobin
(although Y1 levels returned to values very close to
those before donation) and platelet counts, which
declined at M3 and remained significantly lower than
Figure 1. Distributions of laboratory values shown as box plots by time points. Each box spans from the first to the third quartile
and shows the median (line crossing the box) and mean (1). Whiskers extend to the farthest data point within 1.5 IQRs from the box
ends, with all outlying points shown individually as circles.
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predonation values at Y1 [P<0.001]. A subset of
patients (8.9%) had platelet counts below the lower
limit of normal (150 3 103/mm3) as observed in our
previous reports. Graphical representations of the lab-
oratory tests are depicted in Fig. 1. Some of these had
skewed distributions.
The following results are based on all available data.
Because of incomplete follow-up for many donors, we
repeated all the following analyses with only right lobe
donors with complete volume data (predonation, M3,
and Y1 values; n548). Only 1 left lobe donor had
complete volume data, and that donor was excluded
from these analyses. All results were similar to the
results presented when the smaller sample size was
taken into account. These analyses are available in
the supporting information [Supporting Table 1 (cor-
responding to Table 3) and Supporting Figs. 1-6].
Liver and Spleen Volumes Over Time
The mean predonation total liver volume was 1601 cc
(Table 2), and this was on average 2.0% of the donor’s
body weight (range51.4%-5.2%). There were 363
right lobe donors and 25 left lobe donors (6.4%). The
mean right lobe volume was 1067 cc, and the mean
left lobe volume was 599 cc (67% and 33% of the total
liver volume, respectively). The mean predonation
spleen volumes were 2466107 cc; these volumes
substantially increased at M3 and Y1 (paired t tests;
M3, n5165; Y1, n575; P<0.001 for both). The ratio
of the liver volume to the spleen volume was 7.4
before donation, 4.6 at M3, and 5.5 at Y1; the latter 2
values were significantly lower than the predonation
value (paired t tests; M3, n5165; Y1, n575;
P<0.001 for both).
Figure 2A depicts liver volumes with box plots before
donation and at M3 and Y1. Liver volumes were 79% of
the predonation volume at M3 (n5165) and
approached 88% of the predonation volume at Y1
(n575). Predonation liver volumes were highly vari-
able. Even when they were normalized by BSA, liver
volumes varied 2-fold in these healthy subjects; this
pattern was observed at all time points (before dona-
tion, 522-1887 cc; M3, 428-932 cc; and Y1, 542-980
cc). In Fig. 2B, the spaghetti plot demonstrates the
course of liver volumes through resection and regener-
ation as a percentage of the donor predonation liver vol-
ume for individual subjects who had all necessary
measurements (n546). The comparisons of liver vol-
umes at predonation and postdonation time points are
shown individually in Fig. 2C,2D. At both M3 (n5165;
Fig. 2C) and Y1 (n575; Fig. 2D), the majority of livers
were smaller than they were before donation.
With respect to the spleen volumes (Fig. 3), the mean
predonation spleen volume was 2466107 cc, and the
volume ranged from 67 to 775 cc (median5226 cc,
IQR5161-310 cc; Fig. 3A). Even with normalization by
BSA, the range was substantial (40-396 cc/m2),
although larger subjects generally had larger spleens (r2
= 0.52, P<0.001). The spaghetti plot (Fig. 3B) among
donors who had volumes at all 3 time points (n549)
demonstrates the course of the spleen volume over time
with a range as high as 234% of the predonation volume
at Y1. The majority of the subjects had spleen volumes
greater than 100% of the predonation volume at M3 and
Y1. Similarly, Fig. 3C,D (n5165 and n575, respec-
tively) shows the increase in spleen volumes over time.
Relationship Between Spleen Size and Platelet
Counts
There was a highly significant negative association
between the platelet count and the spleen volume at
all time points (before donation, Fig. 4A; M3, Fig. 4B;
and Y1, Fig. 4C) with a relatively consistent slope but
decreasing intercepts over time. The predonation val-
ues are superimposed on Fig. 4B,C to compare post-
donation and predonation data.
Development of a Model for the Prediction of
the Standard Spleen Volume (SSV)
We sought to develop a model for the prediction of the
normal spleen volume in healthy donors before dona-
tion (model A; Table 3). Up to 14 variables were tested
in model selection. The best model included 5 signifi-
cant variables; a larger spleen size was predicted by a
larger predonation liver volume, lower platelet counts,
a larger BSA, a higher hemoglobin level, and a
TABLE 3. Linear Regression Models Predicting Spleen
Volumes
Model and Variable
Parameter
Estimate
P
Value
Model A: predonation spleen volume (n5344,
R250.52)
Predonation liver
volume (per 100 cc)
11.14 <0.001
Platelet count at
evaluation (350,000/mm3)
219.07 <0.001
BSA (cc) 115.22 <0.001
Hemoglobin at
evaluation (g/dL)
11.64 <0.001
Donor age at evaluation
(per 10 years)
213.23 <0.001
Model B: postdonation M3 spleen volume (n5167,
R250.40)
Postdonation M3
liver volume (per 100 cc)
16.43 <0.001
Platelet count at
evaluation (350,000/mm3)
228.46 <0.001
Sex (reference: male) 77.03 <0.001
Model C: postdonation Y1 spleen volume (n575,
R250.42)
Postdonation Y1 liver
volume (per 100 cc)
17.64 <0.001
Platelet count at evaluation
(3 50,000/mm3)
218.01 0.04
Hemoglobin (g/dL) 32.75 <0.001
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younger donor age. With an R2 value of 0.52, the
model performed well for most observed spleen vol-
umes, but the fit suffered in a small group of observed
large spleens for which the model consistently under-
predicted the volumes. A logistic model was fit to pre-
dict the probability of predonation spleen volumes
greater than 400 cc to further investigate the outliers
in the linear regression model, but the significant pre-
dictors were BSA and platelet counts, which were
already seen as predictors of larger spleen volumes in
the SSV model.
Models for Spleen Volume Over Time
First, we assessed the applicability of the SSV model
to postdonation spleen volumes. Using predictions
from the predonation model, Fig. 5 presents predicted
and observed spleen volumes. At M3, we found that
the model consistently underestimated the spleen vol-
umes across all observed volumes. At Y1, underpre-
diction continued, but only in the larger observed
spleen volumes. To investigate whether other varia-
bles might be important for predicting spleen volumes
after liver hepatectomy that were not seen before don-
ation, we developed models to predict postdonation
spleen volumes at both M3 and Y1 [models B
(n5167) and C (n575), respectively; Table 3].
Although sample sizes in both postdonation models
were smaller than those in the predonation model,
lower platelets and larger liver volumes were still seen
as significant predictors of larger spleen volumes.
Lower platelets predicted even larger spleens at M3
than those seen in the models at other time points
(based on parameter estimates in the 3 models);
Figure 2. Liver volumes before donation, after resection (Fig. 2B only), and after donation at M3 and Y1. Volumes are shown as (A) a
box plot by time point (before donation, n5346; M3, n5182; and Y1, n590), (B) a spaghetti plot showing volumes over time as per-
centages of predonation volumes for donors with complete data at all 4 time points (n546), and as scatter plots of (C) the M3 volume
(n5165) and (D) the Y1 volume (n575) plotted against predonation volumes with a diagonal identity line.
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similarly, larger liver volumes predicted slightly larger
spleen volumes in both postdonation models versus
the predonation model. The Y1 model also showed
that higher hemoglobin levels predicted larger spleen
volumes, with nearly 3 times the magnitude seen in
the predonation model. At M3, males were predicted
to have larger spleen volumes. Neither age at donation
nor BSA were significant predictors in either postdo-
nation model. Using predictions from the postdona-
tion models, Fig. 5 also presents predicted and
observed spleen volumes. As seen in the application
of the predonation model to postdonation volumes,
the postdonation models showed underprediction of
the observed large spleen volumes. This suggests that
persistent splenomegaly after donation occurs in a
variety of donors and that changes in such spleen vol-
umes cannot be completely explained through the
application of linear models using patient demo-
graphics and laboratory values alone. Portal vein
thrombosis, although of interest, could not be tested
because only 1 case was reported for the donors in
this analysis.
Effect of the Donated Liver Lobe on the Spleen
Volume
Because right hepatectomy involves resection of more
than half of the liver and results in a smaller remnant
liver, we hypothesized that the impact of donation on
spleen size might be different between right lobe and
left lobe donors. We present the changes in the spleen
volume from the predonation period to the
Figure 3. Spleen volumes before and after donation at M3 and Y1. Volumes are shown as (A) box plots by time point (before donation,
n5346; M3, n5182; Y1, n590), (B) a spaghetti plot showing volumes over time as a percent of predonation volume for donors with
complete data at all 3 time points (n549), and as scatter plots of (C) M3 volume (n5165) and (D) Y1 volume (n575) plotted against
predonation volumes, with a diagonal identity line.
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postdonation period for right and left lobe donors in
Fig. 6. At M3, the average change in spleen volume
(d5M3 value 2 predonation value) was significantly
different between right and left lobe donors (right lobe
mean d572 cc, left lobe mean d541 cc, P50.01,
n5165). At Y1 (d5Y1 value 2 predonation value), the
left lobe effect was even more pronounced (right lobe
mean d566 cc, left lobe mean d5222 cc, P50.2,
n575), although power was limited with only 2 left
lobe donors. Although the samples were small, these
observations are consistent with the possibility that
the extent of hepatic resection is a contributor to the
risk of splenomegaly after donation.
Long-Term Laboratory Abnormalities
We examined laboratory abnormalities beyond Y1 and
found that among the 11 patients with abnormal
platelet counts at either M3 or Y1 who had at least 1
measurement between year 2 and year 4, 8 had
abnormal platelet counts at least 1 time from year 2
to year 4, and this indicated the persistence of this
condition in a subset of patients. The incidence of
complications recorded for donors, however, was not
different for the 12 donors with spleen volumes
greater than 500 cc at Y1 (P50.81).
DISCUSSION
This study demonstrates that thrombocytopenia
observed after living donor hepatectomy is highly cor-
related with persistent changes in spleen size. An
increase in spleen size was observed in nearly all sub-
jects after hepatectomy, with a subset in the abnor-
mal range. Our efforts to develop a predictive model
for spleen size were complicated by the presence of a
subset of subjects skewed toward larger spleen sizes
both before and after liver donation, and this indi-
cates that the biology of this is not subject to simplis-
tic interpretation. Our SSV modeling identified a
number of highly significant predictive variables for
SSV. A population of outliers emerged when this pro-
posed SSV equation was applied to postdonation
measures. Furthermore, separate models developed in
the postdonation setting with a smaller sample of
donors were not able to identify any predictors to suf-
ficiently model these large spleens either. The clinical
significance of these findings will require long-term
study of donors with particular attention to these
subjects.
Understanding the significance of persistent spleno-
megaly after donation is complicated by the paucity of
studies of spleen size in the literature. Pozo et al.13
characterized the spectrum of conditions associated
with splenomegaly, which range from infections to
malignancy. Perhaps more relevant to the population
of potential donors, clinically apparent splenomegaly
was identified in 2.5% of healthy college freshmen,14
none of whom developed clinical disease in over a dec-
ade of follow-up. Among the pathological conditions
associated with splenomegaly, infections and hemato-
logic disorders figure prominently. We observed in the
donor population that the spleen size was critically
related to hematologic parameters even in healthy
subjects. However, most of the published data on
spleen size are from the hematology literature, and
these studies generally have not taken advantage of
3-dimensional volumetrics based on a more advanced
interpretation of integrated sequences from cross-
sectional imaging.
Our efforts to develop a predictive model for spleen
size included liver size as well as a variety of
Figure 4. Scatter plots of platelet counts versus spleen volumes
at 3 time points. On the M3 and Y1 plots, the predonation values
are plotted as gray dots (n5345) behind the postdonation values
(black dots; M3, n5167; Y1, n576). Regression lines are
shown, and the intercepts (b0), slopes (b1), and P values are
given. Values below the lower limit of normal for platelet counts
(150 3 103/mm3) are shown in the gray horizontal bands.
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hematologic parameters. The importance of liver size
in our model can be attributed to the intrinsic rela-
tionship of blood flow between the liver and the
spleen. In a recent cohort of patients with congenital
hepatic fibrosis, a highly significant correlation
between spleen size and platelet counts was
observed.15 Interestingly, however, the authors found
no correlation between hepatic function and platelets
or spleen size, and this is similar to the findings of
the current study, although perhaps albumin is too
superficial a marker of hepatic function to fully
explore this relationship. In addition to its role as an
immune regulator and hematologic modulator, the
spleen has been implicated as a contributor to capaci-
tance in the cardiovascular system,16 and the
splanchnic circulation is a well-known regulator of
intravascular volume. Clearly, the complexities of
these functions are well beyond the capacity of our
study to investigate. Nonetheless, alterations of both
liver volumes and spleen volumes over time are worth
investigating on a more mechanistic level.
The relationship between the regenerating liver and
the spleen is the core issue in the current study
because the subjects selected for donation are clini-
cally healthy and are screened for a broad spectrum
of health conditions. In addition to the simple param-
eters available in the ordinary donor workup, there is
likely to be a relationship between spleen size and
previous exposure to common viruses such as
Epstein-Barr virus, although the variability of such
screening in the donor population did not permit us
to address this issue. Surprisingly little has been
reported on the issue of spleen size, although the
question has been addressed in ultrasonographic
studies of athletes with mononucleosis.17 Our data
reaffirm that liver volume is not restored to the predo-
nation size in the majority of subjects at Y1 despite
normalization of laboratory tests of liver function, and
this is consistent with Pomfret’s early report and a
recent publication from a Korean group with a large
cohort of right lobe donations.9,18,19
Although portal hypertension may influence spleen
size in extreme instances, the relationship between
the not fully regenerated liver and the spleen may also
affect platelet counts because of decreased levels of
thrombopoietin.20 This hormone has been implicated
in platelet development and is decreased in the pres-
ence of liver disease.20-22 In LDLT, Nagasako et al.23
demonstrated that low platelet counts were correlated
with decreased levels of thrombopoietin on day 7 after
liver donation. Thrombopoietin in liver donors has not
been studied in the long term, and in light of our find-
ings, further mechanistic studies are warranted. The
Figure 5. Predicted spleen volumes versus observed spleen volumes by time point. (A) Predonation predicted values calculated with
the predonation spleen volume model (n5345). (B,C) The black dots show postdonation predicted values with the M3 (n5167) and Y1
spleen volume models (n575), respectively, and the light gray dots show predicted values calculated with the predonation spleen vol-
ume model.
Figure 6. Spleen volume changes from before donation to after
donation: a comparison of right and left lobe donors at M3
(P50.01) and Y1 (P50.20). Note that the small numbers of left
lobe donors limit the statistical power. Each box spans from the
first quartile to the third quartile and shows the median (line
crossing the box) and the mean (1). Whiskers extend to the far-
thest data point within 1.5 IQRs from the box ends, with all out-
lying points shown individually as circles.
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overall examination of platelet counts in our patients
indicates that although counts were significantly
lower over time in all subjects, very few fell outside
the normal range. This is similar to the issue of liver
regeneration; although the livers at Y1 were, on aver-
age, 88% of predonation values, none of the subjects
had clinically evident functional impairments. The
Everson study cited earlier10 included a correspond-
ing quantitative liver function assessment that might
yield better information if repeated with a larger num-
ber of patients.
Our data are dependent on the accuracy of cross-
sectional imaging, which has been widely used in
surgical planning in LDLT.24,25 To overcome variabil-
ity in volumetrics associated with center practices
and techniques, we collected all available scans and
re-analyzed them with a central computational labo-
ratory.9-14 In addition, liver and spleen volumes are
not routinely assessed in clinical evaluations of
patients with liver disease, although this is clearly a
useful adjunct in characterizing the course of recov-
ery after liver surgery. Our data demonstrate the
wide variability of liver and spleen sizes in healthy
subjects. Although this is peripheral to the main
aims of this article, we caution against the rigid use
of equations of standard liver volumes in surgical
decision making in hepatectomy. Although it is
sometimes necessary to have an objective norm, the
clinician should be aware of variations among
individuals.
The most important practical question raised by
this study is the clinical significance of persistent
abnormalities of liver and spleen volumes and platelet
counts after donation. Although we have volumetric
data for only a quarter of our subjects at Y1, we have
essentially complete data for the subjects’ laboratory
values, and the correlation of platelet counts with vol-
ume data are consistent over time. Clinical follow-up
of right lobe donors is now well over a decade at many
centers, and few subjects with chronic disease have
been identified. However, we feel strongly that the
small subset of donors who are outliers with respect
to organ volumes and laboratory results merit close
long-term follow-up.
The strengths of the current study include the large
number of subjects and the multicenter collection of
experience, which best reflects the diversity of prac-
tice and experience. Thus, this report is a valuable
complement to the single-center reports on this issue.
Weaknesses include the lack of complete follow-up
with an increasing number of missing scans with time
after donation. Furthermore, an analysis of correlative
mechanistic data will be essential to a better under-
standing of the physiology of splenomegaly after dona-
tion. Finally, the small number of left lobe donors
with complete follow-up has provided some confirma-
tion but prevents us from fully addressing the argu-
ment made by Makuuchi et al.3 that left lobe donors
might fare better than right lobe donors because of
the larger residual liver volume and less portal
hypertension.26
In conclusion, we have confirmed that the persistent
thrombocytopenia observed in living liver donors is
associated with splenomegaly that is persistent up to
1 year after donation. However, abnormalities outside
the normal range are limited to a small number of
subjects. The variability of liver and spleen volumes
before donation is reiterated and reminds us that the
biological complexity bedevils the creation of rigid for-
mulas for surgical planning. Nonetheless, the extreme
outliers clearly need close follow-up to ascertain
whether these findings are harbingers of subclinical
disease that may evolve. The physiologic role of the
spleen after hepatectomy needs further clarification in
two respects, first its role as a regulator of cardiovas-
cular tone mediated by hormones with circulatory
effects, and secondly, whether alterations in thrombo-
poeitin levels alter platelet counts in this setting.
Finally, there is an unquestioned need to extend fol-
low-up for subjects to ascertain the effects of donation
on long-term health.
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